ArticleJournal of cellular and molecular medicine2018
Quercetin impairs Streptococcus pneumoniae biofilm formation by inhibiting sortase A activity.
Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 73 citations in OpenAlex.
- Quercetin as a Natural Adjunct in Managing Plaque and Gingivitis in Adults: A Randomized Controlled Trial.Cureus · 2026Article
- Dryocrassin ABBA Inhibits the Function of LLO and SortaseA to Alleviate the Virulence ofJournal of microbiology and biotechnology · 2026Article
- Maple polyphenols inhibit sortase and drastically reduceMicrobiology spectrum · 2025Article
- Multi-target mechanisms and potential applications of quercetin in the treatment of acne vulgaris.Frontiers in pharmacology · 2025Review
- Article
- Quercetin Exhibits Broad-Spectrum Antibiofilm and Antiquorum Sensing Activities Against Gram-Negative Bacteria: In Vitro and In Silico Investigation Targeting Antimicrobial Therapy.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Current Strategies for Combating Biofilm-Forming Pathogens in Clinical Healthcare-Associated Infections.Indian journal of microbiology · 2024Review
- Current View on Major Natural Compounds Endowed with Antibacterial and Antiviral Effects.Antibiotics (Basel, Switzerland) · 2024Review
- Therapeutic potential activity of quercetin complexes against Streptococcus pneumoniae.Scientific reports · 2024Article
- Fraxetin Targeting to Sortase A Decreases the Pathogenicity ofAnimals : an open access journal from MDPI · 2024Article
- Bavachin Rejuvenates Sensitivity of Colistin against Colistin-Resistant Gram-Negative Bacteria.International journal of molecular sciences · 2024Article
- Impact of Senolytic Treatment on Gene Expression in Aged Lung.International journal of molecular sciences · 2023Article
- Natural Medicine a Promising Candidate in Combating Microbial Biofilm.Antibiotics (Basel, Switzerland) · 2023Review
- Wogonin attenuates the pathogenicity of Streptococcus pneumoniae by double-target inhibition of Pneumolysin and Sortase A.Journal of cellular and molecular medicine · 2023Article
- An Explorative Review on Advanced Approaches to Overcome Bacterial Resistance by Curbing Bacterial Biofilm Formation.Infection and drug resistance · 2023Review
- Article
- Cinnamaldehyde ResistMolecules (Basel, Switzerland) · 2022Article
- An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents.Life (Basel, Switzerland) · 2022Review
- Identification of novel small-molecular inhibitors of Staphylococcus aureus sortase A using hybrid virtual screening.The Journal of antibiotics · 2022Article
- Antimicrobial Activity of Quercetin: An Approach to Its Mechanistic Principle.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm formation mediated by sortase A (srtA) is important for bacterial colonisation and resistance to antibiotics. Thus, the inhibitor of SrtA may represent a promising agent for bacterial infection. The structure of Streptococcus pneumoniae D39 srtA has been characterised by crystallisation. Site-directed mutagenesis was used for the determination of the key residues for the activity of S. pneumoniae D39 srtA. An effective srtA inhibitor, quercetin, and its mechanism was further identified using srtA activity inhibition assay and molecular modelling. In this study, the crystal structure of S. pneumoniae D39 srtA has been solved and shown to contain a unique domain B. Additionally, its transpeptidase activity was evaluated in vitro. Based on the structure, we identified Cys207 as the catalytic residue, with His141 and Arg215 serving as binding sites for the peptide substrate. We found that quercetin can specifically compete with the natural substrate, leading to a significant decrease in the catalytic activity of this enzyme. In cells co-cultured with this small molecule inhibitor, NanA cannot anchor to the cell wall effectively, and biofilm formation and biomass decrease significantly. Interestingly, when we supplemented cultures with sialic acid, a crucial signal for pneumococcal coloniation and the invasion of the host in the co-culture system, biofilm loss did not occur. This result indicates that quercetin inhibits biofilm formation by affecting sialic acid production. In conclusion, the inhibition of pneumococcal srtA by the small molecule quercetin offers a novel strategy for pneumococcal preventative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.